Uscript Author ManuscriptReference1. Doran MF, Crowson CS, Pond GR, et al. Predictors of infection in rheumatoid arthritis. Arthritis Rheumatism. 2002; 46(9):2294sirtuininhibitor00. [PubMed: 12355476] two. Capell HA. Illness modifying antirheumatic drugs: longterm security troubles. J Rheumatol Suppl. 2001; 62:10sirtuininhibitor. Epub 2001/06/21. [PubMed: 11409152] three. Grijalva CG, Chen L, Delzell E, et al. Initiation of tumor necrosis factor-alpha antagonists and also the threat of hospitalization for infection in individuals with autoimmune diseases. JAMA : the journal of the American Medical Association. 2011; 306(21):2331sirtuininhibitor. Epub 2011/11/08. 4. Curtis JR, Patkar N, Xie A, et al. Danger of severe bacterial infections among rheumatoid arthritis sufferers exposed to tumor necrosis factor alpha antagonists. Arthritis Rheum. 2007; 56(4):1125sirtuininhibitor3. [PubMed: 17393394] 5. Curtis JR, Xie F, Chen L, et al. The comparative threat of significant infections among rheumatoid arthritis patients starting or switching biological agents. Ann Rheum Dis. 2011; 70(8):1401sirtuininhibitor. Epub 2011/05/19. [PubMed: 21586439] 6. Curtis JR, Xi J, Patkar N, et al. Drug-specific and time-dependent dangers of bacterial infection amongst individuals with rheumatoid arthritis who had been exposed to tumor necrosis aspect alpha antagonists. Arthritis Rheum. 2007; 56(12):4226sirtuininhibitor. [PubMed: 18050253] 7. Dixon WG, Hyrich KL, Watson KD, et al. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: Final results in the British Society for Rheumatology Biologics Register (BSRBR).Complement C5/C5a Protein manufacturer Ann Rheum Dis.Cyclophilin A Protein supplier 2009 Epub 2009/10/27. eight. Dixon WG, Symmons DP, Lunt M, et al. Severe infection following anti-tumor necrosis aspect alpha therapy in patients with rheumatoid arthritis: lessons from interpreting information from observational studies. Arthritis Rheum. 2007; 56(9):2896sirtuininhibitor04. Epub 2007/09/01. [PubMed: 17763441] 9. Johnston SS, Turpcu A, Shi N, et al.PMID:35567400 Danger of infections in rheumatoid arthritis individuals switching from anti-TNF agents to rituximab, abatacept, or an additional anti-TNF agent, a retrospective administrative claims analysis. Seminars in arthritis and rheumatism. 2013 Epub 2013/03/05. 10. Schneeweiss S, Setoguchi S, Weinblatt ME, et al. Anti-tumor necrosis element alpha therapy and the threat of serious bacterial infections in elderly sufferers with rheumatoid arthritis. Arthritis Rheum. 2007; 56(six):1754sirtuininhibitor4. [PubMed: 17530704] 11. Listing J, Strangfeld A, Kary S, et al. Infections in individuals with rheumatoid arthritis treated with biologic agents. Arthritis Rheum. 2005; 52(11):3403sirtuininhibitor2. [PubMed: 16255017] 12. Dewedar AM, Shalaby MA, Al-Homaid S, et al. Lack of adverse effect of anti-tumor necrosis factor-alpha biologics in therapy of rheumatoid arthritis: 5 years follow-up. International journal of rheumatic ailments. 2012; 15(three):330sirtuininhibitor. Epub 2012/06/20. [PubMed: 22709496] 13. Keyser FD. Decision of Biologic Therapy for Sufferers with Rheumatoid Arthritis: The Infection Point of view. Existing rheumatology reviews. 2011; 7(1):77sirtuininhibitor7. Epub 2011/11/15. [PubMed: 22081766] 14. Furst DE. The danger of infections with biologic therapies for rheumatoid arthritis. Seminars in arthritis and rheumatism. 2010; 39(5):327sirtuininhibitor6. Epub 2009/01/02. [PubMed: 19117595] 15. Hyrich KL, Lunt M, Watson KD, et al. Outcomes just after switching from one anti-tumor necrosis aspect alpha agent to a.